Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.



Published on

Published in: Education
  • Be the first to comment


  2. 2. 5/8/2012 2
  3. 3. 5/8/2012 3
  4. 4. Company Profile Ranbaxy was incorporated in 1961 and went public in 1973. Ranbaxy Laboratories Limited (Ranbaxy), Indias largest pharmaceutical company. It is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. The Company has a global footprint in 43 countries, world-class manufacturing facilities in 8 countries and serves customers in over 125 countries. In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies, globally. 5/8/2012 4
  6. 6. History When we set out on our way in 1961, little did we realize the impact we would make on the Indian and global pharmaceutical industry.  Take a look at how Ranbaxy has grown through the decades......  History1961= Company incorporated1973= Ranbaxy goes public1977=Ranbaxy first joint venture in Lagos (Nigeria) is setup1983= A modern dosage forms facility at Dewas (MP) in India goes onStream.1990= Ranbaxy granted its first US Patent, for doxycline1994=Estabilished regional headquarters in UK and USA . Listed inLuxenburg stock exchange2000= forays in to Brazil, the largest pharmaceutical market in SouthAmerica.2005=Launches operations in Cannada.2011= Celebrates golden jubilee year 5/8/2012 6
  7. 7. Financials For the year 2011, the Company recorded Global Sales of US $ 2.1 Bn. The Company has a balanced mix of revenues from emerging and developed markets that contribute 47% and 46% respectively. In 2011, North America,1. North America, the Companys largest market contributed sales of US $ 791 Mn,2. Europe contributing US $ 297 Mn3. Asia clocking sales of US $ 503 Mn. 5/8/2012 7
  8. 8. Mission/Values Ranbaxys mission is Enriching lives globally, with quality and affordable pharmaceuticals.  Values1. Achieving customer satisfaction if fundamental to our business2. Provides products and services of the highest quality3. Ensure profitable growth and enhance wealth of the shareholders4. Fosters mutually beneficial relations with all our business partners5. Manage our operations with high concern for safety and environment.6. Be a responsible corporate citizen 5/8/2012 8
  9. 9. People The Companys business philosophy based on delivering value to its stakeholders constantly inspires its people to innovate, achieve excellence and set new global benchmarks. Driven by the passion of its over 14,000 strong multicultural workforce comprising of more than 50 nationalities, Ranbaxy continues to aggressively pursue its mission of Enriching lives globally, with quality and affordable pharmaceuticals. Top Management Dr Tsutomu Une Chairman Mr Arun Sawhney: CEO & Managing Director Independent Director1. Dr Anthony H Wild2. Mr Rajesh Shah3. Mr Akihiro Watanabe4. Mr Percy Shroff 5/8/2012 9
  10. 10. CHAIRMAN, CEO AND M.DDr.TsutomuUne Chairman MalvinderMohan Singh CEO &M.D
  11. 11. Products The Company remains focused on ascending the value chain in the marketing of pharmaceutical substances and is determined to bring in increased revenues from dosage forms sales. Ranbaxy robust performance in Cardiovasculars, Central Nervous System, Respiratory, Dermatology, Orthopedic s, Nutritionals and Urology segments, clearly indicates that the Company has strengthened its presence in the fast-growing chronic and lifestyle disease segments. 5/8/2012 11
  13. 13. Recent Acquisitions &AlliancesTerapia (Romania) Zenotech (India)Be-Tabs (South Africa) Krebs (India)Allen (Italy) Jupiter Biosciences*(Ind.)Ethimed (Belgium) Cardinal Drugs (India)Mundogen (Spain) Auto-injector Tech.(USA) * Subject to due diligence
  14. 14. Major Competitors Sun Pharmaceuticals Industries. Cipla. Glaxo smith Kline. Dr. Reddy’s Laboratories 5/8/2012 14
  15. 15. Competition AnalysisName Sales Turnover Net Profit Total AssetsParimal Health 1,350.95 130.72 11,984.78Dr Reddys Labs 5,249.07 893.31 7,465.00Cipla 6,123.84 967.12 7,054.34Sun Pharma 1,933.12 1,383.80 6,731.06Ranbaxy Labs 7,475.90 -3,052.05 6,258.36Lupin 4,508.50 809.98 4,135.95Glenmark 1,154.63 212.18 3,122.86Strides Arcolab 529.44 73.56 2,799.01Cadila Health 2,919.88 610.38 2,653.90Wockharth 1,754.92 -132.07 2,568.61 5/8/2012 15
  16. 16. Business StrategyCurrent• Ranbaxy is focused on increasing the momentum in the generics business in its key markets through organic and inorganic growth routes.Focus• Growth is well spread across geographies with focus on developed and emerging markets.Hybrid Model with Daiichi Sankyo• Endeavour to provide a wide basket of generic and innovator products, leveraging the unique Hybrid Business Model with Daiichi SankyoNew Areas• Focus in high growth potential segments like Vaccines and Biogenerics. (will add significant depth to the existing product pipeline.) 5/8/2012 16
  17. 17. Research and Development Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide a sustainable, long-term competitive advantage. The company has a pool of over 1,200 R&D personnel engaged in path-breaking research. Ranbaxy is among the few Indian pharmaceutical companies in India to have started its research program in the late 70s, in support of its global ambitions. A first-of-its-kind world class R&D centre was commissioned in 1994 5/8/2012 17
  18. 18. R&D: Key Business strategy.R&D is a vital R&D History Daiichi Sankyocomponent of • Since 1970 strategy • first-of-its-kind world • Ranbaxys New Drug• sustainable class R&D centre Discovery Research was commissioned in (NDDR) was• long-term competitive 1994 transferred on July advantage • dedicated facilities for 2010• over 1,200 R&D personnel engaged generics research • Part of the strategy to and innovative strengthen the global in path-breaking research Research and research. Development • Headquartered in Gurgaon 5/8/2012 18
  19. 19. STRATEGIESRanbaxy is focused on increasing the momentum in the genericsbusiness in its key markets through organic and inorganic growthroutes. Growth is well spread across geographies with focus onemerging markets The Company continues to evaluate acquisitionopportunities in India, emerging and developed markets tostrengthen its business and competitiveness. Ranbaxy has forayedinto high growth potential segments like Biologics, Oncology andinjectables. These new growth areas will add significant depth to theexisting product pipeline.The Globalization Strategy Growth Strategy Poised For Growth API Development And Production Dosage Form Development And Manufacturing Contract Manufacturing
  20. 20. Corporate socialResponsibility An essential component of Ranbaxys CSR isto care for the community. Ranbaxy Rural Development Trust in 1978 setup Based on the theme “Health For All” later re-christened as Ranbaxy Community 5/8/2012 20
  21. 21. SWOT ANALYSIS:STRENGTHS: Presence in 23 of the 27 EU countries. Low cost of production. Efficient technologies for large number of Generics. Large pool of skilled technical manpower both in India and abroad. Increasing liberalization of government policies. Well developed industry with Strong manufacturing
  22. 22. Opportunities: Growing incomes. Growing attention for health. New diagnoses and new social diseases. New therapy approaches. Spreading attitude for soft medication (OTC drugs) Spreading use of Generic Drugs. Globalization R&D
  23. 23. WEAKNESS: Fragmentation of installed capacities. Low technology level of Capital Goods of this section. Non-availability of major intermediaries for bulk drugs. Lack of experience to exploit efficiently the new patent regime. Low level of strategic planning for future and also for technology forecasting. Production of Duplicate drugs Absence of Association between Institutes and Industry..
  24. 24. THREATS: Competition From MNCs Containment of rising health-care cost. High Cost of discovering new products and fewer discoveries. Transformation of process patent to product patent. Stricter registration procedures. High entry cost in newer markets. High cost of sales and marketing.
  25. 25. Market Share of Ranbaxy Global MarketsMix 2008 54%& Emerging The Company is currently ranked 2nd in the Indian pharmaceutical market with 4 98%market share (IMS, Oct-D e c·09). Global sales in 2009 were USD 1,519 Mn (Rs. 73,441Mn),De-growth of 9%over previous year. In Rupee terms, sales grew moderately by 1%.Sales during the Quarter recorded growth of 25% at USD 482 Mn (Rs. 22,699 Mn). Emerging markets accounted for54%of sales during the year, while developed markets 5/8/2012 25
  26. 26. Ranbaxy H1 2010 Sales by Market Developed Markets 40% Other 6% Emerging Markets 54%
  27. 27. CONCLUSION Ranbaxy is having a wide range and good products. provides good facilities to their employee. Company has achieved almost its entire desire goal with its hard work and unique idea. As per my opinion that RANBAXY has a wide scope to develop in coming years. 5/8/2012 27
  28. 28. Thank You